Rhonda Duffy Appointed as COO of Biocon Biologics

Biocon Biologics, a subsidiary company of Biocon Ltd announced the appointment of Rhonda Duffy as Chief Operating Officer (COO) on Friday 4th August 2023.

The company also announced the appointment of Sandeep Athalye as the Chief Development Officer. David Gibson is taking over as Global Head – Business Development to oversee all licensing, strategic partnership, and business development efforts.

Rhonda joined Biocon Biologics in July 2023, she brings over 30 years of experience in leadership roles. Rhonda has worked with Leo Pharma for over 30 years. Most recently, as Executive Vice President for Global Product Supply at Leo Pharma, a Denmark-based global dermatology leader, she led end-to-end product supply operations spanning 6 sites and 30 contract manufacturers, the launch of Biologics and the entire Global Product Supply for the Product portfolio worth 1.3 Billion Euro in sales. Rhonda is a qualified pharmacist with a Ph.D. in Pharmacognosy from Trinity College, Dublin.

Sandeep Athalye has over 20 years of experience in Clinical Development and Medical Affairs spanning the US, Europe, and Asia. He spent 12 years in the US with Schering Plough and Novartis, where he was responsible for the global development of assets across several therapeutic areas. He then led the clinical development team at Biocon, before taking up a leadership role at Boehringer Ingelheim in Germany in the Biosimilars Unit. He also has experience in setting up development operations in China.

Sandeep has done a mini MBA in BioPharma Innovation at Rutgers University, New Brunswick, US; an MS in Clinical Pharmacology at the University of Toledo, US and an MBBS in Medicine at the Bharati Vidyapeeth, India.